Extended indications in living-donor liver transplantation: bile duct cancer.
The advantages of living donor liver transplantation are an individually available graft and a tremendously reduced waiting time until transplantation. One consequence is that many centers have extended the pretransplant selection criteria, especially for potential recipients suffering from hepatocellular carcinoma. In contrast, reports on living donor liver transplantation for cholangiocarcinoma are restricted to few case reports. We have analyzed our experience with seven patients suffering from cholangiocarcinoma (Klatskin tumors, n=5; intrahepatic cholangiocarcinoma, n=2). During a median follow-up of 20 months (range 2-46 months), all patients are alive except for one posttransplant death. Four patients suffering from Klatskin tumors are alive without recurrence; both patients suffering from intrahepatic cholangiocarcinoma are alive with bone and peritoneal metastases. Living donor liver transplantation may be beneficial in selected patients suffering from Klatskin tumors, whereas caution should prevail when considering intrahepatic cholangiocarcinoma.
Jonas
Sven
S
Department of General, Visceral and Transplantation Surgery, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany. sven.jonas@charite.de
Mittler
Jens
J
Pascher
Andreas
A
Theruvath
Tom
T
Thelen
Armin
A
Klupp
Jochen
J
Langrehr
Jan M
JM
Neuhaus
Peter
P
D001650:Bile Duct Neoplasms; D018281:Cholangiocarcinoma; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation; D019520:Living Donors / Q000145:classification*; D018579:Patient Selection; D012189:Retrospective Studies; D020858:Tissue and Organ Harvesting